Pancreatic cancer (PC, mostly pancreatic ductal adenocarcinoma, PDAC) is one of the deadliest cancers, with a median survival of less than 1 year and a 5-year survival of only about 10%. 80% of patients with PDAC are inoperable at diagnosis, and there is no curative treatment for advanced PDAC. Alfa Oncology is a full-scale contract research organization (CRO) with extensive experience. We are committed to providing a range of PC research and drug development services to our global clients ranging from pharmaceutical, biotechnology, and research institutions. Our scientific innovation platform is driven by the expertise of our highly qualified team of scientists and is supported by state-of-the-art infrastructure as well as market-leading technology. We are proud to offer a range of drug development services for PC, involving small molecule drug development, peptide drug development, antibody drug development, nucleic acid drug development, cellular immunotherapy development, and oncolytic viral therapy development.
Small molecule compounds are a new type of targeted therapeutic agent and have become a hot topic in the research of tumors, including PC. There are many advantages of small molecule compounds, including ease of structural modification, better suitability for clinical needs (they can be taken orally as tablets), ease of storage and transport, and lower cost. We are pleased to offer the following small molecule drug development services for PC:
-Target discovery & validation
-Hit identification and lead generation
-Preclinical safety assessment
With the incorporation of different stable structural modifications and new drug delivery systems, short peptides have proven to be promising drugs for cancer therapy. Peptides are attracting attention in the development of anti-tumor drugs because of their targeting, safety, and specificity. We are proud to offer the following peptide drug development services for PC:
-Screening for peptides targeting PC
-Peptide design and optimization
-Custom peptide synthesis
-Validation and evaluation for peptides targeting PC
With years of experience in therapeutic antibody discovery, in-depth knowledge of PC biology, a team of industrial experienced experts, and advanced research equipment and methods, we are able to provide a one-stop service for your early-stage antibody drug discovery and accelerate your antibody drug development process for targeting PC.
-mAb discovery and production for PC
-mAb optimization for PC
-Preclinical research of mAb for PC
Nucleic acid therapy can modify pathogenic and drug-resistant genes, insert tumor suppressor genes, and has great potential in PC therapy. We understand nucleic acid and pharmaceutical services and are committed to integrating our nucleic acid production and nucleic acid drug delivery system development capabilities to help our customers achieve nucleic acid therapy development.
-ASO drug development for PC
-siRNA drug development for PC
-miRNA-based therapy development for PC
-CircRNA-based therapy development for PC
-Aptamer-based therapy development for PC
PC has the ability to immune escape by mechanisms that include immunosuppression of the dense fibrotic tumor microenvironment and overall low tumor mutational burden. Cellular immunotherapy, involving chimeric antigen receptor (CAR)-T cell, natural killer (NK) cells, and tumor-infiltrating lymphocytes (TILs), has the potential to eliminate cancer cells by restoring cancer immunity.
-CAR-T cell therapy development for PC
-CAR-NK cell therapy development for PC
-TIL therapy development for PC
With a better understanding of PC genes and molecular mechanisms, oncolytic viral therapy has shown potential as a new targeted therapeutic approach in PC treatment. Based on viral biology, immunology and genetic engineering, we have successfully developed oncolytic therapy development services for PC.
-Oncolytic virus design and construction
-Oncolytic virus in vitro and in vivo assay
-Oncolytic virus manufacturing
As a leading service provider in PC drug development, we continue to expand our services and improve our available resources to help our clients accelerate their research and support their careers. For more about our services, please contact us. We are glad to work with you!